German pharmaceutical company Merck Life Science has commenced the construction of a new bioprocessing production center in Daejeon, marking its largest investment in the Asia-Pacific region with an estimated 300 million euros ($325 million) commitment. The facility, situated on a 43,000-square-meter site within Daejeon's International Science-Business Belt, aims for completion by 2026. CEO Matthias Heinzel emphasized the significance of this venture, highlighting its role in providing essential biotech products to meet the manufacturing demands of biotech and pharmaceutical companies in South Korea and the broader Asia-Pacific region. Upon completion, the center will offer critical materials for the clinical manufacture of advanced biopharmaceuticals, contributing to Merck Life Science's 'in-region, for-region' manufacturing strategy and bolstering supply chain resilience in the rapidly growing region. Additionally, the facility will support process development, clinical research, and commercial production of biologics, while creating approximately 300 new jobs in Daejeon. South Korea's Trade Minister Cheong In-kyo lauded this investment, recognizing its potential to enhance the country's biopharmaceutical manufacturing capabilities and stimulate the local economy. The groundbreaking ceremony was attended by key figures including Merck Life Science CEO Heinzel, Trade Minister Cheong, and Daejeon Mayor Lee Jang-woo, underscoring the significance of this milestone. Moreover, Merck Life Science has forged a partnership with the Korea Advanced Institute of Science and Technology for collaborative research in the biopharmaceutical sector.